Marshall Wace LLP lifted its stake in Cabot Co. (NYSE:CBT - Free Report) by 3,242.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,338 shares of the specialty chemicals company's stock after buying an additional 72,114 shares during the period. Marshall Wace LLP owned about 0.14% of Cabot worth $6,788,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank acquired a new position in Cabot during the fourth quarter worth $37,961,000. Copeland Capital Management LLC increased its position in shares of Cabot by 21.6% during the 4th quarter. Copeland Capital Management LLC now owns 761,372 shares of the specialty chemicals company's stock worth $69,521,000 after purchasing an additional 135,119 shares in the last quarter. American Century Companies Inc. lifted its holdings in Cabot by 8.5% during the 4th quarter. American Century Companies Inc. now owns 1,323,347 shares of the specialty chemicals company's stock valued at $120,835,000 after purchasing an additional 103,380 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Cabot by 27.1% in the fourth quarter. JPMorgan Chase & Co. now owns 451,513 shares of the specialty chemicals company's stock valued at $41,228,000 after buying an additional 96,179 shares in the last quarter. Finally, Lightrock Netherlands B.V. bought a new stake in Cabot during the fourth quarter worth about $6,228,000. Institutional investors own 93.18% of the company's stock.
Cabot Stock Performance
CBT stock opened at $78.42 on Thursday. The company has a 50 day moving average price of $82.25 and a 200 day moving average price of $94.24. Cabot Co. has a fifty-two week low of $73.63 and a fifty-two week high of $117.46. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.00 and a quick ratio of 1.29. The stock has a market capitalization of $4.25 billion, a PE ratio of 10.41, a price-to-earnings-growth ratio of 0.74 and a beta of 1.04.
Cabot (NYSE:CBT - Get Free Report) last released its earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a return on equity of 26.79% and a net margin of 10.60%. Analysts forecast that Cabot Co. will post 7.57 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on CBT shares. UBS Group cut their target price on shares of Cabot from $93.00 to $83.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. JPMorgan Chase & Co. cut their price objective on Cabot from $105.00 to $85.00 and set an "underweight" rating for the company in a research report on Friday, February 21st. StockNews.com upgraded Cabot from a "hold" rating to a "buy" rating in a report on Thursday, April 17th. Finally, Mizuho lowered their target price on Cabot from $122.00 to $110.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th.
Get Our Latest Stock Report on Cabot
Cabot Company Profile
(
Free Report)
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Further Reading
Want to see what other hedge funds are holding CBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cabot Co. (NYSE:CBT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cabot, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.
While Cabot currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
